

1 **Clinical evaluation of a disposable amperometric magneto-genosensor for**  
2 **the detection and identification of *Streptococcus pneumoniae***

3  
4 Alma Sotillo<sup>1,2</sup>, María Pedrero<sup>3</sup>, Manuela de Pablos<sup>1</sup>, José Luis García<sup>2</sup>,  
5 Ernesto García<sup>2,4</sup>, Pedro García<sup>2,4</sup>, José Manuel Pingarrón<sup>3</sup>, Jesús  
6 Mingorance<sup>1\*</sup>, Susana Campuzano<sup>3\*</sup>

7  
8 1, Servicio de Microbiología, Hospital Universitario La Paz, IdiPAZ, Paseo de la  
9 Castellana, 261, 28046, Madrid, Spain

10 2, Departamento de Microbiología Molecular y Biología de las Infecciones,  
11 Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, 28040  
12 Madrid, Spain

13 3, Departamento de Química Analítica, Facultad de CC. Químicas, Universidad  
14 Complutense de Madrid, 28040 Madrid, Spain

15 4, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias  
16 (CIBERES, Instituto de Salud Carlos III), Carretera Sóller km 12, Bunyola,  
17 07110 Mallorca, Illes Balears, Spain

18  
19 \*corresponding authors: S. Campuzano, e-mail: [susanacr@quim.ucm.es](mailto:susanacr@quim.ucm.es); tel:

20 [34913944368](tel:34913944368); fax: [34913944329](tel:34913944329); and J. Mingorance, e-mail:

21 [jesus.mingorance@idipaz.es](mailto:jesus.mingorance@idipaz.es); tel: 34912071364; fax: 34917277372.

22  
23 Running title: Electrochemical sensor for pneumococci

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

26

27 **Abstract** A disposable PCR-based amperometric magneto-genosensor for  
28 detection and identification of *Streptococcus pneumoniae* was evaluated. ROC  
29 curve analysis used to determine optimal signal cutoff values yielded a  
30 sensitivity of 91 % and a specificity of 90 %. The method was also tested for the  
31 direct detection of pneumococci in clinical samples.

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 **Keywords:** *Streptococcus pneumoniae*, *Streptococcus mitis* group, biosensors,  
47 *lytA* gene

48

1 49 The streptococci of the Mitis group (SMG) include the closely related species  
2  
3 50 *Streptococcus pneumoniae*, *Streptococcus mitis*, *Streptococcus*  
4  
5 51 *pseudopneumoniae* and *Streptococcus oralis*, which possess significantly  
6  
7 52 different pathogenic properties and antimicrobial susceptibility patterns.  
8  
9 53 Differentiation between pneumococci and other SMG is clinically relevant and is  
10  
11 54 typically done by phenotypic (e.g., optochin susceptibility testing and/or bile  
12  
13 55 solubility assay) and/or serological methods (Lund and Henrichsen, 1978). The  
14  
15 56 methods that require bacterial culturing are time-consuming, while  
16  
17 57 immunochromatographic methods are rapid but present cross-reactivity  
18  
19 58 problems in some patient groups (Blaschke, 2011).  
20  
21

22  
23 59 To improve accuracy and speed diagnosis, new methods based on the  
24  
25 60 polymerase chain reaction (PCR) have been developed (Harris et al., 2008;  
26  
27 61 Rouphael et al., 2008; Sheppard, 2004; Smith et al., 2009). Several *S.*  
28  
29 62 *pneumoniae*-specific markers have been proposed among which the most  
30  
31 63 relevant are the *ply* and *lytA* genes, which encode the pneumolysin (Marriott et  
32  
33 64 al., 2008) and the main autolysin (López and García, 2004), respectively.  
34

35 65 Homologs of the *lytA* gene of *S. pneumoniae* have also been found in other  
36  
37 66 SMG but characteristic features in the pneumococcal gene have allowed the  
38  
39 67 design of a specific PCR assay (Llull et al., 2006; Obregón et al., 2002).  
40

41 68 Electrochemical DNA biosensors, also called genosensors, are based on the  
42  
43 69 integration of a sequence-specific probe and an electrochemical signal  
44  
45 70 transducer, and offer an interesting detection method (Drummond et al., 2003;  
46  
47 71 Lucarelli et al., 2008) which is easy to implement, with low instrumentation  
48  
49 72 costs, and the possibility for accurate and sensitive detection in small sample  
50  
51 73 volumes (Wei et al., 2010).  
52

53  
54 74 Magnetic beads (MBs) facilitate efficient target retrieval and concentration,  
55  
56 75 reduce the assay time and favor higher sample throughput and automation  
57  
58 76 (Chen et al., 2007). The use of MBs enhances sensitivity and reduces detection  
59  
60  
61  
62  
63  
64  
65

1 77 time in electrochemical genosensors (Bettazzi et al., 2013; Campuzano et al.,  
2 78 2011; Pedrero et al., 2012).

3  
4  
5 79 We present an evaluation of the performance of a recently described  
6  
7 80 amperometric magneto-genosensor for the identification of *S. pneumoniae*  
8  
9 81 (Campuzano et al., 2011) using a collection of microbial isolates and clinical  
10  
11 82 samples in comparison with standard microbiological identification procedures.  
12  
13 83 The sensor uses a specific DNA capture probe for the detection of a  
14  
15 84 characteristic *lytA* single-stranded DNA fragment amplified by asymmetric PCR  
16  
17 85 (aPCR) (Fig. 1). Both, the capture probe and the single-stranded amplicon are  
18  
19 86 biotinylated. Streptavidin-modified MBs are loaded with the capture probe, the  
20  
21 87 loaded beads are then hybridized with the aPCR product, and the hybrid  
22  
23 88 molecules are labeled with streptavidin-peroxidase polymer (Strep-HRP). The  
24  
25 89 modified MBs are captured by a magnetic field on the surface of  
26  
27 90 tetrathiafulvalene (TTF)-modified gold screen-printed electrodes (Au/SPEs) and  
28  
29 91 the peroxidase activity is measured as the amperometric response at  $-0.15$  V  
30  
31 92 upon  $H_2O_2$  addition.

32  
33  
34 93 Microbial isolates ( $n = 107$ ) were identified by Vitek 2 (BioMérieux SA, Marcy  
35  
36 94 l'Etoile, France) or Wider systems (Francisco Soria Melguizo SA, Madrid,  
37  
38 95 Spain), MALDI-TOF mass spectrometry (Bruker Daltonics, GmbH, Bremen,  
39  
40 96 Germany) and optochin test.

41  
42  
43 97 Clinical samples ( $n = 109$ ) were obtained from skin, abscesses, sputum,  
44  
45 98 purulence, blood, swabs taken from throat, ear or conjunctiva, nasal, tracheal or  
46  
47 99 bronchial aspirates, pleural fluid and bronchoalveolar washes. All the samples  
48  
49 100 were obtained in the Microbiology Department of Hospital La Paz, and had  
50  
51 101 been anonymized previously, keeping only microbiological data.

52  
53 102 DNA (from agar plate cultures or from clinical samples) was extracted using  
54  
55 103 the UltraClean<sup>®</sup> Microbial DNA Isolation Kit (MoBio, Carlsbad, CA USA). When  
56  
57 104 required, clinical samples were fluidised with 0.7% dithiothreitol (final  
58  
59 105 concentration) before extracting DNA.

1 106 The magneto-genosensing strategy has been recently described  
2  
3 107 (Campuzano et al., 2011). Briefly, streptavidin-coated MBs were loaded with the  
4  
5 108 biotinylated DNA capture probe and hybridized with the amplicon generated by  
6  
7 109 aPCR (biotinylated reverse to forward primer ratio of 8:1). The hybrid-attached  
8  
9 110 beads were washed twice with 500  $\mu$ L of Tris–HCl (pH 7.2) and labeled with  
10  
11 111 streptavidin-peroxidase polymer. The enzyme-tagged hybrid-MBs assemblies  
12  
13 112 were washed five times (2 min each) with 500  $\mu$ L of PBST (PBS containing  
14  
15 113 0.05% Tween<sup>®</sup>20), and once more with 500  $\mu$ L of PBS (10 mM sodium  
16  
17 114 phosphate buffer solution containing 137 mM NaCl and 2.7 mM KCl, pH 7.5).  
18  
19 115 The MBs were resuspended in 45  $\mu$ L of PBS and magnetically captured on the  
20  
21 116 surface of gold screen-printed electrodes (220AT, 4-mm  $\varnothing$ , Dropsens, Spain)  
22  
23 117 by placing a neodymium magnet under the working electrode surface. TMB-  
24  
25 118 H<sub>2</sub>O<sub>2</sub> K-Blue reagent solution (Neogen, Lexington, KY) in a ready-to-use format  
26  
27 119 (K-Blue enhanced-activity substrate, also containing H<sub>2</sub>O<sub>2</sub>) was used as  
28  
29 120 substrate, and amperometric measurements were done with a single-channel  
30  
31 121 amperometric detector (InBea Biosensores S. L., Madrid, Spain). Statistical  
32  
33 122 analyses were done using SPSS 17.0. The continuous output obtained from  
34  
35 123 amperometric measurements was transformed into a binary classification by  
36  
37 124 ROC curve analysis. The optimal cutpoint value was determined as the point on  
38  
39 125 the ROC curve closest to (0.1) and the Youden index (Perkins and  
40  
41 126 Schisterman, 2006), which maximize sensitivity and specificity.  
42  
43 127 Genosensor performance was tested with a series of 107 cultured microbes  
44  
45 128 obtained from clinical samples. Seventy nine had been classified as *S.*  
46  
47 129 *pneumoniae* (Sp) and twenty eight were non-pneumococcal isolates  
48  
49 130 (designated as N-Sp): 25 streptococci [*Streptococcus anginosus* (2 strains),  
50  
51 131 *Streptococcus gallolyticus* (1 strain), *Streptococcus intermedius* (3 strains), *S.*  
52  
53 132 *mitis* (8 strains), *S. oralis* (4 strains), *Streptococcus pyogenes* (4 strains),  
54  
55 133 *Streptococcus salivarius* (1 strain), *Streptococcus sanguinis* (1 strain) and  
56  
57 134 *Streptococcus suis* (1 strain)], and three non-streptococcal microbes, *i.e.*,

1 135 *Staphylococcus lugdunensis*, *Enterococcus faecalis* and *Candida albicans*. All  
2  
3 136 the samples were tested in duplicate. Two blanks were included in each PCR  
4  
5 137 run to control reagent contamination and were also processed to determine the  
6  
7 138 baseline of the amperometric measurements. Typically, the blanks (n = 102)  
8  
9 139 gave signals around -100 nA. To minimize inter-assay variation the sample  
10  
11 140 signals were normalized dividing them by their corresponding blanks. The  
12  
13 141 average of the normalized ratios was 7.55 for Sp isolates and 1.15 for N-Sp  
14  
15 142 species (Fig. 2A). An optimal cutoff value of 1.92 for the sample to blank ratio  
16  
17 143 was estimated from ROC curve analysis (Fig. 2C). The same value was  
18  
19 144 obtained with the ROC (0.1) and the Youden indexes. The area under the curve  
20  
21 145 (AUC) was 0.94 [95 % confidence interval (CI) 0.89–0.98]. Using a normalized  
22  
23 146 value >1.92 as the threshold to identify *S. pneumoniae*, 73 out of 79  
24  
25 147 pneumococci and 25 out of 28 non-pneumococci were correctly identified. With  
26  
27 148 this cutoff, the assay had a sensitivity of 91 % (95 % CI 85–97 %) and a  
28  
29 149 specificity of 90 % (95 % CI 79–100 %) (Table I). The seven false negative and  
30  
31 150 the three false positive (two *S. mitis* and one *S. pyogenes*) results were tested  
32  
33 151 and their identity was confirmed by *lytA* PCR and 16S rRNA gene  
34  
35 152 pyrosequencing (data not shown).

36  
37  
38 153 The ability of the method to directly detect *S. pneumoniae* in complex clinical  
39  
40 154 samples was tested. A series of 109 samples of diverse origins that had been  
41  
42 155 previously used for microbiological diagnostic were collected (Table II and Fig.  
43  
44 156 2B). Total DNA was extracted and a fixed volume (5  $\mu$ L) was used for aPCR of  
45  
46 157 the *lytA* gene. *S. pneumoniae* had been identified in 60 samples. In 44 of them,  
47  
48 158 the genosensor gave a positive identification, while in 16 the results were  
49  
50 159 negative. The remaining 49 samples included 7 samples in which no growth  
51  
52 160 was detected, 13 samples containing mixed saprophytic microbiota, and 29  
53  
54 161 samples in which some other pathogen had been identified (including several  
55  
56 162 streptococci and staphylococci, *Pseudomonas* sp., *Acinetobacter baumannii*, *E.*  
57  
58 163 *coli*, *Enterobacter cloacae*, *Haemophilus influenzae*, *Moraxella catarrhalis*,

1 164 *Stenotrophomonas maltophilia*, *Candida parapsilosis* and *C. albicans*). In 39 of  
2  
3 165 these 49 samples the genosensor results were negative ( $\leq 1,92$ ), while 10  
4  
5 166 samples were positive. Five of these were polymicrobial and four were sterile.

6  
7 167 With the cutoff selected, both sensitivity and specificity were around 90 %.  
8  
9 168 PCR retesting and 16S gene pyrosequencing of conflicting samples suggested  
10  
11 169 that the source of variability is the processing of amplicons (including binding to  
12  
13 170 MBs, washing of loaded MBs and their magnetic capture on the working  
14  
15 171 electrode surface) for amperometric measurement, rather than the PCR or the  
16  
17 172 amperometric measurement itself. Along this line, ongoing work on automation  
18  
19 173 of magnetogenosensor preparation is directed to reduce processing time and  
20  
21 174 inter-assay variability.

22  
23 175 Evaluation of the genosensor with a set of clinical samples showed its  
24  
25 176 feasibility for the direct detection of pneumococci in a wide variety of samples  
26  
27 177 ranging from blood, pleural fluids to conjunctival swabs. The false negatives  
28  
29 178 found and the fact that about half of them had amperometric ratios near the  
30  
31 179 cutoff point suggests that detection might be improved using specific cutoff  
32  
33 180 points for the different sample types. The positive results found in some sterile  
34  
35 181 samples suggests that the genosensor might be detecting DNA from dead  
36  
37 182 bacteria.

38  
39 183 The use of disposable sensors and commercial MBs makes magneto-  
40  
41 184 biosensing platforms an interesting approach for the detection of pathogens,  
42  
43 185 which can be integrated into portable, multiplexed and automatic devices  
44  
45 186 without requiring special human or material resources.

46  
47  
48  
49  
50  
51 187 **Acknowledgements** This work was funded by a grant from the Ministerio  
52  
53 188 de Ciencia e Innovación (IPT-2011-1337-010000). CIBER de Enfermedades  
54  
55 189 Respiratorias (CIBERES) is an initiative of the Instituto de Salud Carlos III. The  
56  
57 190 financial support of the AVANSENS Program from the Comunidad de Madrid  
58  
59 191 (S2009PPQ-1642) is gratefully acknowledged.

1 192  
2  
3  
4 193  
5  
6 194  
7  
8  
9 195  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Conflict of Interest**

The authors declare that they have no conflict of interest.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

196 **References**

197 Bettazzi, F., Hamid-Asl, E., Esposito, C.L., Quintavalle, C., Formisano, N.,  
198 Laschi, S., Catuogno, S., Iaboni, M., Marrazza, G., Mascini, M., Cerchia, L.,  
199 De Franciscis, V., Condorelli, G., Palchetti, I., 2013. Electrochemical  
200 detection of miRNA-222 by use of a magnetic bead-based bioassay. *Anal.*  
201 *Bioanal. Chem.* 405, 1025–34.

202 Blaschke, A.J., 2011. Interpreting assays for the detection of *Streptococcus*  
203 *pneumoniae*. *Clin. Infect. Dis.* 52 Suppl 4, S331–7.

204 Campuzano, S., Pedrero, M., García, J.L., García, E., García, P., Pingarrón,  
205 J.M., 2011. Development of amperometric magnetogenosensors coupled to  
206 asymmetric PCR for the specific detection of *Streptococcus pneumoniae*.  
207 *Anal. Bioanal. Chem.* 399, 2413–20.

208 Chen, L., Deng, L., Liu, L., Peng, Z., 2007. Immunomagnetic separation and  
209 MS/SPR end-detection combined procedure for rapid detection of  
210 *Staphylococcus aureus* and protein A. *Biosens. Bioelectron.* 22, 1487–92.

211 Drummond, T.G., Hill, M.G., Barton, J.K., 2003. Electrochemical DNA sensors.  
212 *Nat. Biotechnol.* 21, 1192–9.

213 Harris, K., Turner, P., Green, E., Hartley, J., 2008. Duplex real-time PCR assay  
214 for detection of *Streptococcus pneumoniae* in clinical samples and  
215 determination of penicillin susceptibility. *J. Clin. Microbiol.* 46, 2751–8.

216 Llull, D., López, R., García, E., 2006. Characteristic signatures of the *lytA* gene  
217 provide a basis for rapid and reliable diagnosis of *Streptococcus*  
218 *pneumoniae* infections. *J. Clin. Microbiol.*


219 López, R., García, E., 2004. Recent trends on the molecular biology of  
220 pneumococcal capsules, lytic enzymes, and bacteriophage. *FEMS*  
221 *Microbiol. Rev.* 28, 553–80.

222 Lucarelli, F., Tombelli, S., Minunni, M., Marrazza, G., Mascini, M., 2008.  
223 Electrochemical and piezoelectric DNA biosensors for hybridisation  
224 detection. *Anal. Chim. Acta* 609, 139–59.



225 Lund, E., Henrichsen, J., 1978. Laboratory diagnosis, serology and  
226 epidemiology of *Streptococcus pneumoniae*, in: Bergan, T., Norris, J.R.  
227 (Eds.), *Methods in Microbiology*. Academic Press, London, pp. 241–262.

228 Marriott, H.M., Mitchell, T.J., Dockrell, D.H., 2008. Pneumolysin: a double-  
229 edged sword during the host-pathogen interaction. *Curr. Mol. Med.* 8, 497–  
230 509.

231 Obregón, V., García, P., García, E., Fenoll, A., López, R., García, J.L., 2002.  
 232 Molecular peculiarities of the *lytA* gene isolated from clinical pneumococcal  
 233 strains that are bile insoluble. *J. Clin. Microbiol.* 40, 2545–54.  
 234 Pedrero, M., Campuzano, S., Pingarrón, J.M., 2012. Magnetic Beads-Based  
 235 Electrochemical Sensors Applied to the Detection and Quantification of  
 236 Bioterrorism/Biohazard Agents. *Electroanalysis* 24, 470–482.  
 237 Perkins, N.J., Schisterman, E.F., 2006. The inconsistency of “optimal” cutpoints  
 238 obtained using two criteria based on the receiver operating characteristic  
 239 curve. *Am. J. Epidemiol.* 163, 670–5.  
 240 Roupheal, N.G., Atwell-Melnick, N., Longo, D., Whaley, M., Carlone, G.M.,  
 241 Sampson, J.S., Ades, E.W., 2008. A real-time polymerase chain reaction  
 242 for the detection of *Streptococcus pneumoniae* in blood using a mouse  
 243 model: a potential new “gold standard”. *Diagn. Microbiol. Infect. Dis.* 62,  
 244 23–5.  
 245 Sheppard, C.L., 2004. Autolysin-targeted LightCycler assay including internal  
 246 process control for detection of *Streptococcus pneumoniae* DNA in clinical  
 247 samples. *J. Med. Microbiol.* 53, 189–195.  
 248 Smith, M.D., Sheppard, C.L., Hogan, A., Harrison, T.G., Dance, D.A.B.,  
 249 Derrington, P., George, R.C., 2009. Diagnosis of *Streptococcus*  
 250 *pneumoniae* infections in adults with bacteremia and community-acquired  
 251 pneumonia: clinical comparison of pneumococcal PCR and urinary antigen  
 252 detection. *J. Clin. Microbiol.* 47, 1046–9.  
 253 Wei, F., Lillehoj, P.B., Ho, C.-M., 2010. DNA diagnostics: nanotechnology-  
 254 enhanced electrochemical detection of nucleic acids. *Pediatr. Res.* 67,  
 255 458–68.  
 256  
 257  
 258



**Fig. 1.** Scheme of the amperometric detection of the pneumococcal *lytA* gene: magnetic beads (MBs) are loaded with capture probe and this is hybridized with *lytA* single-stranded aPCR product which is then labeled with streptavidin-HRP. MBs are captured by a magnetic field over the surface of a TTF-Au/SPE electrode. To determine the amount of aPCR product the peroxidase activity over the electrode is measured by amperometric detection of the reduction of  $\text{H}_2\text{O}_2$  with TTF.



**Fig. 2** Boxplot of normalized amperometric values obtained with 107 microbial isolates (A) or 109 clinical samples (B). The line within the boxes indicates the median, the boxes span the interquartile range. (C) ROC curve of the signal-to-blank ratio obtained with the magneto-amperometric genosensor for microbial isolates (AUC = 0.94).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

308 **Table I** Genosensor assay results obtained with DNA purified from  
309 cultured microbial isolates<sup>a</sup>

		Microbiological identification		
		Sp	N-Sp	Total
Magneto-genosensor results	Sp	72	3	75
	N-Sp	7	25	32
	Total	79	28	107

311 <sup>a</sup> Sp, *Streptococcus pneumoniae*; N-Sp, non-pneumococcal microorganisms.

312  
313

314 **Table II** Genosensor assay results obtained with total DNA purified directly  
 315 from clinical samples

316

	<i>Streptococcus pneumoniae</i>		Others	
	GS+	GS-	GS+	GS-
Abscess	1		1**	3
BAL	2			2
BAS	10	6	1*	14
Bilis			1**	
Blood	1			
Conjunctival swab	9	1		
Nasal aspirate	3	1	2**	2
Otical	4	2	1	
Pleural Fluid	1		1*	2
Skin				2
Sputum	12	6	1**	8
Tissue				1
Tracheal aspirate	1		1*	4
Urine			1*	
Wound				1
	44	16	10	39

317

318 \* sterile samples; \*\* polymicrobial samples

319

320

Figure(s)

